MicroPort is a leading provider of medical solutions, driven by the belief in the universal right to high-quality medical treatment. Founded in 1998, for over 25 years, the company has been dedicated to breaking barriers and accelerating access to life-changing technologies. Operating in over 100 countries and 20,000 hospitals, MicroPort provides advanced solutions for more than 200 diseases across 12 key therapeutic areas, impacting millions of lives globally.
The company has received a significant CNY3.50B Private Equity Round investment on 07 September 2020. The investors include Citic PE, Hillhouse Investment, Biolink Capital, Grand Flight Investment, E Fund Management Co.,LTD.
With a global footprint encompassing R&D and manufacturing facilities across China, United States, France, Italy, and Dominican Republic, MicroPort is committed to shaping the future of healthcare. The company's dedication to innovation is evident through deep collaboration with the medical community, emphasizing attention to detail in the development of medical technologies to ensure the enhancement of every little moment in the lives of millions of people.
MicroPort's mission is to ensure better and longer lives for patients worldwide, and it is poised for an exciting path forward, addressing the most challenging healthcare issues while exploring ways to impact even more lives every second.
For more information, visit www.microport.com.
Read the community guidelines here.
This analysis showcases MicroPort's global presence, strong commitment to innovation, and the substantial Private Equity Round investment received in 2020, demonstrating its potential for monumental growth and impact in the healthcare industry.
